GlassScriptPhysician profile
Richard M Bryan
NPI 1508952953
$270,296.78
in general payments reported to CMS, 2019-2025
33 companies · $82K in 2025
The $82K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $23K · 2021: $24K · 2022: $24K · 2023: $24K · 2024: $31K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $106K · Travel and Lodging: $14K · Food and Beverage: $14K · Consulting Fee: $4,200 · Gift: $40.59 · Education: $32.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $105,910.00 |
| Travel and Lodging | $13,901.96 |
| Food and Beverage | $13,545.45 |
| Consulting Fee | $4,200.00 |
| Gift | $40.59 |
| Education | $32.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $187,834.76 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $42,580.22 | 2019 | |
| Horizon Therapeutics Plc | $13,216.35 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $6,971.00 | 2021-2025 | Lupkynis |
| Abbvie INC. | $5,433.84 | 2019-2025 | Rinvoq, Skyrizi |
| Genentech USA, INC. | $4,746.50 | 2019-2025 | Actemra |
| Janssen Biotech, INC. | $4,104.36 | 2019-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $971.13 | 2021-2025 | Saphnelo |
| Pfizer INC. | $901.10 | 2019-2025 | |
| Ucb, INC. | $841.25 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $659.09 | 2021-2025 | Benlysta |
| Amgen INC. | $380.13 | 2019-2025 | Tavneos, Krystexxa, Otezla |
| Janssen Scientific Affairs, LLC | $325.97 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $252.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $232.75 | 2019-2024 | Orencia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $144.30 | 2023-2024 | Hadlima, Renflexis |
| Genentech, INC. | $127.00 | 2019 | |
| Ani Pharmaceuticals, INC. | $119.40 | 2022-2023 | Purified Cortrophin Gel |
| Sandoz INC. | $61.97 | 2024-2025 | Hyrimoz |
| Lilly USA, LLC | $55.20 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $46.67 | 2024-2025 | |
| Genzyme Corporation | $37.91 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $35.22 | 2024 | Arcalyst |
| Fresenius Kabi USA, LLC | $25.92 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $25.07 | 2024 | Truxima |
| Celltrion USA INC. | $24.53 | 2023 | Yuflyma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.51 | 2025 | |
| Fidia Pharma USA INC. | $23.85 | 2024 | Hyalgan, Hymovis, Triluron |
| Hikma Pharmaceuticals USA | $21.60 | 2020 | |
| Sobi, INC | $19.46 | 2022 | |
| Antares Pharma, INC. | $18.68 | 2020 | |
| Merck Sharp & Dohme LLC | $17.33 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.